2022 Discrepancies in the management of Clostridioides difficile infections in patients after allogeneic haematopoietic cell transplantation: the results of the Infectious Diseases Working Party EBMT survey Group Infectious Diseases Working Party (IDWP) 1st listed author Agnieszka Piekarska Journal Bone Marrow Transplant.
2022 The first steps towards a diverse and inclusive EBMT: a position paper Group Patient Advocacy Committee Equality, Diversity & Inclusion (ED&I) Committee 1st listed author S Montoto Journal Bone Marrow Transplant.
2022 Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis Group Inborn Errors Working Party (IEWP) 1st listed author Michael H Albert Journal Blood.
2022 Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Giorgia Battipaglia Journal Bone Marrow Transplant.
2022 Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Juan-Carlos Hernández-Boluda Journal Bone Marrow Transplant.
2022 Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Ryszard Swoboda Journal Bone Marrow Transplant.
2022 Mother donors improve outcomes after HLA haploidentical transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the EBMT Group Cellular Therapy & Immunobiology Working Party (CTIWP) 1st listed author Loredana Ruggeri Journal Transplant Cell Ther.
2022 Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Am J Hematol.
2022 Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author Hind Alotaibi Journal Transplant Cell Ther.
2022 Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Stavroula Masouridi-Levrat Journal Bone Marrow Transplant.
2021 Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Frédéric Baron Journal Bone Marrow Transplant.
2021 Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Jaime Sanz Journal J Hematol Oncol.